Evidence map›Paper›PMID 40141405›Full record

ArticleInternational journal of molecular sciences2025

Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines.

Ann Morcos, Yeonkyu Jung, Ryan N Fuller, Antonella Bertucci, Amy Nguyen, Quanqing Zhang, Tobias Emge, Kristopher E Boyle, Nathan R Wall, Marcelo Vazquez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ann MorcosDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
Yeonkyu JungDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.ORCID 0009-0005-9443-5383
Ryan N FullerDepartment of Biological Sciences, California Baptist University, Riverside, CA 92504, USA.ORCID 0000-0001-7067-4500
Antonella BertucciDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
Amy NguyenProteomics Core, Institute for Integrative Genome Biology, University of California, Riverside, CA 92521, USA.
Quanqing ZhangProteomics Core, Institute for Integrative Genome Biology, University of California, Riverside, CA 92521, USA.
Tobias EmgeDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.
Kristopher E BoyleSchool of Pharmacy, Loma Linda University, Loma Linda, CA 92399, USA.
Nathan R WallDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.ORCID 0000-0002-3235-4386
Marcelo VazquezDepartment of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is among the most lethal primary brain tumors and is characterized by significant cellular heterogeneity and resistance to conventional therapies. This study investigates the efficacy of seco-duocarmycin SA (seco-DSA), a novel DNA alkylating agent. Initial investigations using a colony formation assay revealed that seco-DSA exhibits remarkable potential with IC

Indexed as

Brain NeoplasmsGlioblastomaIndolesApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalDuocarmycinsHumansDuocarmycinsIndolescellular mechanismsduocarmycinglioblastoma multiformepotencyproof of conceptresistanceseco-DSA

Identifiers

PMID40141405
PMCPMC11943345

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.